申请人:Nogradi Katalin
公开号:US20090326001A1
公开(公告)日:2009-12-31
The present invention relates to new mGluR1 and niGluR5 receptor subtype preferring ligands of formula (I): wherein X represents a group selected from (CH
2
)
n
, CH═CH, NH, N(CH
3
), NHCH
2
, N(CH
3
)CH
2
, O, OCH
2
, CH
2
COO, NHCH
2
COO; n is an integer of 0 to 2; Y represents a subtituent selected from H, CH
3
, F, Cl, Br; Z is H or CH
3
; R is alkyl, cycloalkyl, an optionally substituted phenyl or an optionally substituted heteroaryl, and/or geometric isomers and/or salts and/or hydrates and/or solvates thereof, to the processes for producing the same, to pharmaceutical compositions containing the same and to their use in therapy and/or prevention of pathological conditions which require the modulation of mGluR1 mGluR5 receptors such as neurological disorders, psychiatric disorders, acute and chronic pain and neuromuscular dysfunctions of the lower urinary tract.
本发明涉及一种新的mGluR1和niGluR5受体亚型优选配体的公式(I):其中X代表从(CH2)n,CH═CH,NH,N(CH3),NHCH2,N(CH3)CH2,O,OCH2,CH2COO,NHCH2COO中选择的基团;n是0到2的整数;Y代表H,CH3,F,Cl,Br中选择的取代基;Z是H或CH3;R是烷基,环烷基,可选取代的苯基或可选取代的杂环基,以及它们的几何异构体和/或盐和/或水合物和/或溶剂化物,以及制备它们的过程,包含它们的制药组合物以及它们在治疗和/或预防需要调节mGluR1 mGluR5受体的病理状态,如神经系统疾病、精神障碍、急性和慢性疼痛以及下泌尿道神经肌肉功能障碍中的应用。